



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/988,493	11/20/2001	Herath Modiyanselage Athula Chandrasiri Herath	2543-1-024	8554

23565 7590 01/05/2004  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601

EXAMINER

UNGAR, SUSAN NMN

ART UNIT PAPER NUMBER

1642

DATE MAILED: 01/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. <b>09/988,493</b>	Applicant(s) <b>Herath et al</b>
Examiner <b>Ungar</b>	Art Unit <b>1642</b>

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on Oct 27, 2003
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-44 is/are pending in the application.
- 4a) Of the above, claim(s) 1-7 and 20-44 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claims 8-19 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some\* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☐ Other:

Art Unit: 1642

1. The Election filed October 27, 2003 in response to the Office Action of September 23, 2003 is acknowledged and has been entered. Claims 1-7 and 20-44 have been withdrawn from further consideration by the examiner under 37 CFR 1.142(b) as being drawn to non-elected inventions. Claims 8-19 are currently under prosecution.

2. Applicant's election with traverse of Group II, claims 8-19 is acknowledged. The traversal is on the ground(s) that the inventions have not been shown to be independent and the examination of all groups would not impose a serious burden on the examiner. This is not found persuasive. MPEP 802.01 provides that restriction is proper between inventions which are independent or distinct. Here, the inventions of the various groups are distinct for the reasons set forth in Paper No.

11. As to the question of burden of search, the inventions are classified differently, necessitating different searches in the US Patent shoes. Further, classification of subject matter is merely one indication of the burdensome nature of the search involved. The literature search, particularly relevant in this art, is not coextensive and is much more important in evaluating the burden of search. Different searches and issues are involved in the examination of each group. For these reasons the restriction requirement is deemed to be proper and is therefore made FINAL.

3. Upon review and reconsideration, Restriction to one of the following inventions is required under 35 U.S.C. § 121:

**Group 1**, claims 8-12 drawn to a method for diagnosis/screening for stage and severity of breast cancer comprising detecting at least one BPI selected from the group of 190 BPI claimed in claim 8, classified in Class 435,

Art Unit: 1642

subclasses 4 and 7.1. It is noted that by factorial analysis, Group 1 consists of  $9.6 \times 10^{351}$  combinations of BPIs, therefore the inventions of this group are drawn to  $9.6 \times 10^{351}$  distinct inventions. Applicant is required to elect a single specific group for examination. It is noted for Applicant's convenience that **this is not an election of species requirement**, but rather a requirement for the election of a single invention for prosecution.

**Group 2**, claims 8-12 drawn to a method for diagnosis/screening for monitoring the effect of therapy on breast cancer comprising detecting at least one of the BPI selected from the group of 190 BPI classified in Class 435, subclasses 4 and 7.1. It is noted that by factorial analysis, Group 2 consists of  $9.6 \times 10^{351}$  combinations of BPIs, therefore the inventions of this group are drawn to  $9.6 \times 10^{351}$  distinct inventions. Applicant is required to elect a single specific group for examination. It is noted for Applicant's convenience that **this is not an election of species requirement**, but rather a requirement for the election of a single invention for prosecution.

**Group 3**, claims 8-12 drawn to a method for prognosis/screening for identifying a patient at risk for breast cancer comprising detecting at least one of the BPI selected from the group of 190 BPI claimed in claim 8 classified in Class 435, subclasses 4 and 7.1. . It is noted that by factorial analysis, Group 3 consists of  $9.6 \times 10^{351}$  combinations of BPIs, therefore the inventions of this group are drawn  $9.6 \times 10^{351}$  independent inventions. Applicant is required to elect a single specific group for examination. It is noted for Applicant's

Art Unit: 1642

convenience that **this is not an election of species requirement**, but rather a requirement for the election of a single invention for prosecution.

**Group 4**, claims 13-14 are drawn to a preparation comprising an isolated BPI selected from the 190 claimed in claim 13 classified in Class 530, subclass 100+. Applicant is required to elect a single specific BPI for examination. It is noted for Applicant's convenience that **this is not an election of species requirement**, but rather a requirement for the election of a single invention for prosecution.

**Group 5**, claims 15-19 are drawn to an antibody that binds to one of the 190 BPI claimed in Claim 15, classified in Class 530, subclass 386.1. Applicant is required to elect a single specific antibody for examination. It is noted for Applicant's convenience that **this is not an election of species requirement**, but rather a requirement for the election of a single invention for prosecution.

4. The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups 4 and 5 as disclosed are biologically and chemically distinct, unrelated in structure and function, made by and used in different methods and are therefore distinct inventions.

Inventions of Groups 1-3 are materially distinct methods which differ at least in objectives, method steps, reagents and/or dosages and/or schedules used, response variables, and criteria for success.

Further the inventions Groups 1-3 are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that

Art Unit: 1642

(1) the patentability of the combination does not rely necessarily and solely on the patentability of any one subcombination and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the patentability of the combination does not rely necessarily and solely on the patentability of any one subcombination as clearly evidenced by the plural subcombinations claimed. Further, each of the subcombinations has utility by itself because each of the subcombinations are useful for screening for different variables and different markers. Thus the claims are distinct as required by MPEP 806.05(c).

The inventions of Groups 4/5 and 1-3 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (I) the process for using the product as claimed can be practiced with another materially different product or (ii) the product as claimed can be used in a materially different process of using that product [see *MPEP* § 806.05(h)]. In the instant case the protein product and antibody product as claimed each be used in a materially different process such as affinity chromatography.

5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matter, restriction for examination purposes as indicated is proper.

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R.

§ 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship

Art Unit: 1642

must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

8. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.


9. **Please Note:** In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Anthony Caputa, Ph.D., Supervisory Patent Examiner at 703-308-3995. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

Art Unit: 1642

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (703) 305-2181. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (703) 308-3995. The fax phone number for this Art Unit is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.



Susan Ungar  
Primary Patent Examiner  
December 24, 2003